Advanced search
Publication Cover
Expert Review of Vaccines Volume 3, 2004 - Issue 2
Submit an article Journal homepage
130
Views
44
CrossRef citations to date
0
Altmetric
Miscellaneous

Recombivax-HB: perspectives past, present and future

Charmaine Venters Louisiana State University Health Sciences Center, Louisiana State University Health Sciences Center, Earl K. Long Hospital/AssistantProfessor Department of Pediatrics,5828 Airline Highway, Baton Rouge, LA 70805, USA. [email protected]
,
William Graham Louisiana State University Health Sciences Center, Louisiana State University Health Sciences Center, Earl K. Long Hospital/AssistantProfessor Department of Pediatrics,5828 Airline Highway, Baton Rouge, LA 70805, USA. [email protected]
&
William Cassidy Louisiana State University Health Sciences Center, Louisiana State University Health Sciences Center, Earl K. Long Hospital/AssistantProfessor Department of Pediatrics,5828 Airline Highway, Baton Rouge, LA 70805, USA. [email protected]
Pages 119-129 | Published online: 09 Jan 2014

References

  • The Centers for Disease Control (CDC). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 40(RR-13), 1–25 (1991).
  • Chang MH, Chen JC, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Eng. J. Med 336, 1855–1859 (1997).
  • Krugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain): studies on active immunization. JAMA 217,41–45 (1971).
  • McQuillan GM, Colemen PJ, Kruszon-Moran D et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am.j Public Health 89,11–13 (1999).
  • Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin. Liver Dis. 11, 84–92 (1991).
  • World Health Organization (WHO). Progress in the control of viral hepatitis: Memorandum from a WHO meeting. Bulletin WHO 66,453–455 (1988).
  • Melnick JL. Historical aspects of hepatitis B vaccine. In: Hepatitis B Vaccine Inserm. Symp. No. 18. Maupas P, Guesry P (Eds), Elsevier/North-Holland Biomedical Press, Amsterdam, Netherlands 23–31 (1991).
  • Seeff LB, Wright EC, Zimmerman HJ et al. Type B hepatitis after needle stick exposure: prevention with hepatitis B immunoglobulin. Final report of the Veterans Administration Cooperative Study. Ann. Int. Med. 88,285–293 (1978).
  • The Centers for Disease Control (CDC). Inactivated hepatitis B virus vaccine. MMWR 31, 317–328 (1982).
  • The Centers for Disease Control (CDC). Recommendations of the Immunisation Practices Advisory Committee: Recommendations for protection against viral hepatitis. MMWR 34,329–335 (1985).
  • International Group. Immunization against hepatitis B. Lancet 1, 875–876 (1988).
  • WHO. Informal consultation in quadrivalent diptheria—tetanus—pertussis—hepatitis B vaccine: final report. Geneva: WHO 1–12 (1992).
  • Francis DP, Feorino PM, McDougal S et id. The safety of the hepatitis B vaccine: Inactivation of the AIDS virus during routine manufacture. JAMA 25,869–871 (1986).
  • McAleer W-J, Buynak EB, Maigetter RZ et al. Human hepatitis B vaccine from recombinant yeast. Nature 307,178–180 (1984).
  • Emini EA, Ellis RW, Miller W-J et al. Production and immunological analysis of recombinant hepatitis B vaccine. J. Infect. 13(Suppl. A), 3–9 (1986).
  • Davidson M, Krugman S. Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose. J. Infect. 13(Suppl. A), 31–38 (1986).
  • Jilg W, Lorbeer B, Schmidt Metal. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 2,1174–11 (1984).
  • Davidson M, Krugman S. Immunogenicity of recombinant yeast hepatitis B vaccine. Lancet 1,108–109 (1985).
  • Papaevangelou G, Dandolos E, Roumeliotou-Karayannis A et al. Immunogenicity of recombinant hepatitis B vaccine. Lancet 1,455–456 (1985).
  • Brow SE, Stanley C, Howard CR et al. Antibody responses to recombinant and plasma-derived hepatitis B vaccine. Br. MedJ. 292, 159–161 (1986).
  • Hollinger FB, Troisi CL, Pepe PE. Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast. J. Infect. Dis. 153,156–159 (1986).
  • CDC. Recommendations of the Immunization Practices Advisory Committee update on hepatitis B prevention. MMWR 36,353–366 (1987).
  • WHO. Progress in the control of viral hepatitis: Memorandum from a WHO meeting. Bull WHO 66,443–455 (1988).
  • Kane MA, Bezabeh S. Hepatitis B vaccination: challenges and solutions. In: Viral Hepatitis and Liver Disease. Rizzetto M, Murcell RH, Gerin JL, Verme G (Eds), Edizioni Minerva Medica, Turin, Italy 938–939 (1997).
  • CDC. Recommendations of the immunization practices advisory committee: recommendations for protection against viral hepatitis. MMWR 34,329–335 (1985).
  • Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J. InfDis. 160,766-769 (1989).
  • Wong V, Woodruff C, Shapiro R. Compliance of hepatitis B vaccination in patients presenting to a teenage clinic. Ped. InfDis.J. 13,936 (1994).
  • Cassidy W, Mahoney F. A hepatitis B vaccination program targeting adolescents. J. Ada Health 17, 244–247 (1995).
  • The Centers for Disease Control (CDC). Notice to readers: alternate two-dose hepatitis B vaccination schedule for adolescents aged 11–15 years. MMWR 49, 261 (2000).
  • Cassidy W, Watson B, Ioli V et al. A randomized trail of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 107, 626–631 (2001).
  • Poland G. Adolescent hepatitis B immunization: making it simpler. Pediatrics 107, 771–772 (2001).
  • The Centers for Disease Control (CDC). Effectiveness of a seventh-grade school entry vaccination requirement-statewide and Orange County, Florida, 1997–1998. MMWR 47,711–715 (1998).
  • The Centers for Disease Control (CDC). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee. MMWR 40(RR-13), 1–25 (1991).
  • Stevens C, Toy P, Tong M et al. Perinatal hepatitis B virus transmission in the United States. /AMA 253,1740–1744 (1985).
  • Kumar M, Dawson N, McCollough A et al. Should all pregnant women be screened for hepatitis B. Ann. Int. Med 107,272–277 (1987).
  • CDC. MMWR 33,285-290 (1984) and MMWR 34,313–324; 329–335 (1985).
  • Jonas M, Schiff E, O'Sullivan Metal. Failure of Centers for Disease Control criteria to identify hepatitis B infection in a large municipal obstetrical population. Ann. Int. Med. 107,335–337 (1987).
  • McMahon B, Heyward W, Ritter D et al. A comprehensive program to reduce the incidence of hepatitis B virus infection and its sequela in Alaskan Natives. Lancet 1134–1135 (1987).
  • Durand AM, Sabino H JR, Mahoney F. Success of mass vaccination of infants against hepatitis B. JAMA 276,1802–1803 (1996).
  • Stevens C, Taylor P, Tong M et al. Yeast recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 257,2612–2616 (1987).
  • Lolekha S, Warachit B, Hirunyachote A et al. Protective efficacy of hepatitis B without HBIG in infants of HBsAg-positive carrier mothers in Thailand. Vaccine 20, 3739–3743 (2002).
  • Franks A, Berg C, Kane M et al. Hepatitis B virus infection among children born in the United States to southeast Asian refugees. N Eng.J. Med. 321,1301–1304 (1989).
  • Keyserling H, West D, Hesley T et al. Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four, and twelve to fifteen months of age. J. Pedai tr. 125, 67–69 (1994).
  • West D, Watson B, Lichtman J, Hesley T, Hedberg K. Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. J. Ped. Inf Dis. 13,645–646 (1994).
  • CDC. Notice to readers: FDA approval of changes in pediatric formulation for Recombivax-HB®. MMWR 48,34–35 (1999).
  • Advisory Committee on Immunization Practices. Redbook. Pickering L (Ed.), American Academy of Pediatrics, IL, USA 24–25 (2003).
  • American Academy of Pediatrics Committee on Infectious Diseases. Universal hepatitis B immunization. Pediatrics 37,585–601 (1992).
  • Kim S, Chung E, Hodinka R et al. Immunogenicity of hepatitis B vaccine in preterm infants. Pediatrics 99,534–536 (1997).
  • Chirico B, Belloni C, Gasparoni A et al. Hepatitis B immunization in infants of hepatitis B surface antigen-negative mothers. Pediatrics 92,717–719 (1993).
  • Del Canho R, Grosheide P, Gerards L et al. Hepatits B vaccination and preterm infants. J. Ped. Inf Dis. 12,407–408 (1993).
  • Chawareewong S, Jirapongsa A, Lokaphadhana K. Immune response to hepatitis B vaccine in premature neonates. Southeast Asian Trap. Med. Public Health 22,39–40 (1991).
  • Lau K, Tam A, et al. Response of preterm infants to hepatitis B vaccine. J. Pedai tr. 121,962–965 (1992).
  • Losonsky J, Wasseramn S, West D et al. Hepatitis B vaccination in preterm infants; a reassessment of current recommendations for delayed immunization. Pediatrics 103, 2 (1999).
  • Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 272, 54–60 (1996).
  • Wilson JN, Nokes DJ. Do we need three doses of hepatitis B vaccine? Vaccine 17, 2667–2673 (1999).
  • Wistrom J, Ahlm C, Lundberg S et al. Booster vaccination with recombinant hepatitis B vaccine 4 years after priming with one single dose. Vaccine 17, 2162–2165 (1999).
  • Jilg W, Schmidt M, Deinhardt F. Immune response to hepatitis B revaccination. J. Med. Viral. 24,377–384 (1985).
  • Biggar RJ, Goedert JJ, Hoofnagle J. Acclerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. N Engl J. Med. 316,630–631 (1987).
  • The Centers for Disease Control (CDC). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee. MMWR 40(RR-13), 1–25 (1991).
  • The Centers for Disease Control (CDC). MMWR Recommendations and Reports 50 (RR-05), 1–43 (2001).
  • Seto D, West D, Ioli V. Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth. J. Ped. Inf Dis. 21, 793–794 (2002).
  • Marsano L, West D, Chan I et al. A two- dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine 16(6), 624–629 (1998).
  • Ostrow DJ, Goldsmith J et al. Nonresponse to hepatitis B vaccine in homosexual men. Sex. Transm. Dis. 14,92–97 ( 1987).
  • Janssen H, Hess G, Rossol S et al. Antiviral effect of prolonged intermittent lymphoblastoid interferon treatment in chronic hepatitis B. Gut 33(8), 1094–1098 (1992).
  • Andre FE. Summary of efficacy and safety data on a yeast-derived hepatitis B vaccine. Am. J. Med. 87(Suppl. 3A), 14S-20S (1989).
  • WHO. Expanded Programme on Immunisation (EPI). Lack of evidence that hepatitis B vaccine causes multiple sclerosis. Wkly Epidemiol. Rec. 72,149–152 (1997).
  • Ascherio A, Zhang SM, Hernan MA et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J. Med. 344, 327–332 (2001).
  • Confraveux C, Suissa S, Saddier P et at. Vaccination and the risk of relapse in multiple sclerosis. N Engl J. Med. 344, 327–332 (2001).
  • SadonvickAD, Scheifele DW. School-based hepatitis B vaccination program and adolescent multiple sclerosis. Lancet 355, 549–550 (2000).
  • The Centers for Disease Control (CDC). MMWR 49(27), 622–631 (2000).
  • West D, Hesley T, Jonas L et al. Safety and immunogenicity of a bivalent Haemophilus influenzae type b/Hepatitis B vaccine in healthy infants. J. Ped. Inf Dis. 16, 593–599 (1997)•.
  • Chang MH, Chen JC, Lai MS et al.Universal hepatitis B vaccination in Taiwan and the incidence of heaptocellular carcinoma in children. N Eng. J. Med. 336, 1855–1859 (1997).

WebSites

  • Website of the Hepatitis B Foundation. www.hepb.org Accessed March, 2004.
  • World Health Organization documents. www.who.int/vaccines-documents/DoxNe ws/pdf-updt/updat31e.pdf Accessed March, 2004.
  • Website of the National Center for Infectious Diseases, Travellers' Health. www.cdc.gov/travel/diseases/hbv.htm Accessed March, 2004.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.